TY - JOUR
T1 - Fructose and sugar
T2 - A major mediator of non-alcoholic fatty liver disease
AU - Jensen, Thomas
AU - Abdelmalek, Manal F.
AU - Sullivan, Shelby
AU - Nadeau, Kristen J.
AU - Green, Melanie
AU - Roncal, Carlos
AU - Nakagawa, Takahiko
AU - Kuwabara, Masanari
AU - Sato, Yuka
AU - Kang, Duk Hee
AU - Tolan, Dean R.
AU - Sanchez-Lozada, Laura G.
AU - Rosen, Hugo R.
AU - Lanaspa, Miguel A.
AU - Diehl, Anna Mae
AU - Johnson, Richard J.
N1 - Funding Information:
RJJ and ML discloses they are inventors on patents related to blocking fructose metabolism as a means to reduce sugar craving and metabolic syndrome. RJJ, LGL, DRT, and ML also have equity in Colorado Research Partners LLC, which is a startup company interested in developing novel fructokinase inhibitors. Dr Johnson has also received honoraria from Danone, Astra Zeneca and is on the Scientific Board of Kibow, Inc. RJJ, ML and TJ have submitted a patent for V1b antagonists for the treatment of IR and fatty liver disease. LGS-L receives research support from Danone Research and Kibow Biotech, Inc. MK, MG, CR, YS, KJN, DHK SS, KJN, MFA, AMD, HRR do not have any relevant disclosures. Please refer to the accompanying ICMJE disclosure forms for further details.
Funding Information:
AMD and MFA receive funding support from NIH/ NIDDK (PI: Diehl; DK 061,703-09 and MPI: Abdelmalek: R01DK093568). KDH is supported by a grant of National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (NRF-2015R1A2A1A15053374, NRF-2017R1A2B2005849).
Publisher Copyright:
© 2018 European Association for the Study of the Liver
PY - 2018/5
Y1 - 2018/5
N2 - Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome; its rising prevalence parallels the rise in obesity and diabetes. Historically thought to result from overnutrition and a sedentary lifestyle, recent evidence suggests that diets high in sugar (from sucrose and/or high-fructose corn syrup [HFCS]) not only increase the risk of NAFLD, but also non-alcoholic steatohepatitis (NASH). Herein, we review the experimental and clinical evidence that fructose precipitates fat accumulation in the liver, due to both increased lipogenesis and impaired fat oxidation. Recent evidence suggests that the predisposition to fatty liver is linked to the metabolism of fructose by fructokinase C, which results in ATP consumption, nucleotide turnover and uric acid generation that mediate fat accumulation. Alterations to gut permeability, the microbiome, and associated endotoxemia contribute to the risk of NAFLD and NASH. Early clinical studies suggest that reducing sugary beverages and total fructose intake, especially from added sugars, may have a significant benefit on reducing hepatic fat accumulation. We suggest larger, more definitive trials to determine if lowering sugar/HFCS intake, and/or blocking uric acid generation, may help reduce NAFLD and its downstream complications of cirrhosis and chronic liver disease.
AB - Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome; its rising prevalence parallels the rise in obesity and diabetes. Historically thought to result from overnutrition and a sedentary lifestyle, recent evidence suggests that diets high in sugar (from sucrose and/or high-fructose corn syrup [HFCS]) not only increase the risk of NAFLD, but also non-alcoholic steatohepatitis (NASH). Herein, we review the experimental and clinical evidence that fructose precipitates fat accumulation in the liver, due to both increased lipogenesis and impaired fat oxidation. Recent evidence suggests that the predisposition to fatty liver is linked to the metabolism of fructose by fructokinase C, which results in ATP consumption, nucleotide turnover and uric acid generation that mediate fat accumulation. Alterations to gut permeability, the microbiome, and associated endotoxemia contribute to the risk of NAFLD and NASH. Early clinical studies suggest that reducing sugary beverages and total fructose intake, especially from added sugars, may have a significant benefit on reducing hepatic fat accumulation. We suggest larger, more definitive trials to determine if lowering sugar/HFCS intake, and/or blocking uric acid generation, may help reduce NAFLD and its downstream complications of cirrhosis and chronic liver disease.
KW - Hepatic inflammation
KW - Hepatic steatosis
KW - Insulin resistance
KW - Sugar consumption
KW - Uric acid
UR - http://www.scopus.com/inward/record.url?scp=85042418281&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2018.01.019
DO - 10.1016/j.jhep.2018.01.019
M3 - Review article
C2 - 29408694
AN - SCOPUS:85042418281
SN - 0168-8278
VL - 68
SP - 1063
EP - 1075
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 5
ER -